2,141 results match your criteria Angioimmunoblastic Lymphoma


Clinical spectrum, evolution and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.

Eur J Haematol 2019 Apr 15. Epub 2019 Apr 15.

Service de médecine interne, Hôpital Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est, Créteil, France.

Objective: Angioimmunoblastic T-cell lymphoma (AITL) are frequently associated with autoimmune cytopenia (AIC). Whether such patients have a particular phenotype and require particular management is unclear.

Method: AITL patients from the multicentric database of the Lymphoma Study Association presenting with AIC during disease course were included and matched to AITL patients without AIC (1/5 ratio). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.13239DOI Listing
April 2019
1 Read

Cutaneous Lesions of Angioimmunoblastic T-cell Lymphoma: Clinical, Pathological, and Immunophenotypic Features.

J Cutan Pathol 2019 Apr 12. Epub 2019 Apr 12.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.

Background: Angioimmunoblastic T-cell lymphoma (AITL) is a systemic peripheral T-cell lymphoma with a follicular helper T-cell (T ) immunophenotype that frequently involves the skin. However, the histopathology of cutaneous involvement by AITL has not been fully established.

Methods: We reviewed the clinicopathological features of 19 patients seen at our institution with AITL involving the skin. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.13475
Publisher Site
http://dx.doi.org/10.1111/cup.13475DOI Listing
April 2019
4 Reads

Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases.

Mod Pathol 2019 Apr 5. Epub 2019 Apr 5.

Department of Pathology and Laboratory Medicine, Nagoya University Hospital, Nagoya, Japan.

Methotrexate-associated lymphoproliferative disorders are categorized as "other immunodeficiency-associated lymphoproliferative disorders in the WHO classification. Methotrexate-associated lymphoproliferative disorder is mainly a B-cell lymphoproliferative disorders or Hodgkin lymphoma type, whereas T-cell lymphoproliferative disorders are relatively rare (4-8%). Only a small number of methotrexate-associated T-cell lymphoproliferative disorders have been detailed thus far. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0264-2DOI Listing
April 2019
2 Reads

The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations.

Mod Pathol 2019 Apr 5. Epub 2019 Apr 5.

Institute of Pathology and Neuropathology, Eberhard Karls University of Tübingen and Comprehensive Cancer Center, Tübingen University Hospital, Tübingen, Germany.

Angioimmunoblastic T-cell lymphoma is a peripheral T-cell lymphoma derived from follicular T-helper cells. High-throughput genomic sequencing studies have shown that angioimmunoblastic T-cell lymphoma carries frequent mutations in RHOA and IDH2 genes. The clinico-pathological features of angioimmunoblastic T-cell lymphoma cases with RHOA mutations have been addressed; however, similar studies for IDH2 mutated cases are lacking. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0254-4DOI Listing
April 2019
3 Reads

FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.

Oncologist 2019 Mar 26. Epub 2019 Mar 26.

Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, Silver Spring, Maryland, USA.

In November 2018, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin (BV) for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0098DOI Listing
March 2019
3 Reads

Moving Toward Targeted Therapy in the Treatment of Angioimmunoblastic T-Cell Lymphoma.

Authors:
Pamela B Allen

J Oncol Pract 2019 Mar;15(3):145-146

1 The Winship Cancer Institute of Emory University, Atlanta, GA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00749DOI Listing
March 2019
1 Read

Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma.

J Oncol Pract 2019 Mar;15(3):137-143

1 Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.

Patients with angioimmunoblastic T-cell lymphoma (AITL), one of the most common types of peripheral T-cell lymphoma (PTCL), typically present with advanced disease, systemic symptoms, and immune deregulation. Treatment can be challenging owing to frequent relapses after initial and subsequent therapy. The front-line treatment approach currently mirrors the approach used for other nodal PTCLs with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and consideration for autologous stem-cell transplant (SCT). Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JOP.18.00511
Publisher Site
http://dx.doi.org/10.1200/JOP.18.00511DOI Listing
March 2019
5 Reads

Unravelling Subtleties of Angioimmunoblastic T-Cell Lymphoma.

J Oncol Pract 2019 Mar;15(3):147-148

1 Hôpital Lyon Sud and Université Claude Bernard Lyon 1, Pierre-Bénite, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.19.00089DOI Listing

Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival.

Ups J Med Sci 2019 Mar 11:1-6. Epub 2019 Mar 11.

c Department of Medical Sciences, Section of Infectious Diseases , Uppsala University , Uppsala , Sweden.

Background: In cancer, regulatory T-cells (Tregs) were previously believed to inhibit tumor immunity, leading to reduced survival. However, in hematologic malignancies, including T-cell lymphoma (TCL), a correlation between increased numbers of tumor-infiltrating Tregs and a favorable prognosis has been reported. We aimed to investigate the expression of the Treg biomarker forkhead box protein 3 (FoxP3) in TCL in immunocompetent individuals and explore a possible correlation to overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/03009734.2018.1555195DOI Listing

Rare diseases that mimic Systemic Lupus Erythematosus (Lupus mimickers).

Joint Bone Spine 2019 Mar 26;86(2):165-171. Epub 2018 Oct 26.

Centre national de référence des maladies autoimmunes et systémiques rares Est Sud-Ouest (RESO)-LUPUS, 67000 Strasbourg, France; Service de rhumatologie, hôpitaux universitaires de Strasbourg, 67098 Strasbourg, France; Université de Strasbourg, Inserm UMR-S 1109, 67000 Strasbourg, France. Electronic address:

Several conditions have clinical and laboratory features that can mimic those present in Systemic Lupus Erythematosus (SLE). Some of these "SLE mimickers" are very common, such as rosacea which can be mistaken for the butterfly rash, while others such as Kikuchi disease, type-1 interferonopathies, Castleman's disease, prolidase deficiency, angioimmunoblastic T-cell lymphoma, Evans' syndrome in the context of primary immune deficiencies and the autoimmune lymphoproliferative syndrome are exceptionally uncommon. A proper diagnosis of SLE must therefore be based upon a complete medical history as well as on the adequate constellation of clinical or laboratory findings. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S1297319X183042
Publisher Site
http://dx.doi.org/10.1016/j.jbspin.2018.10.007DOI Listing
March 2019
10 Reads

Metronidazole-induced encephalopathy during treatment for refractory diarrhea after cord blood transplantation.

Clin J Gastroenterol 2019 Mar 5. Epub 2019 Mar 5.

Department of Hematology, Kyoto University Hospital, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, , 606-8507, Japan.

A 56-year-old man underwent cord blood transplantation for angioimmunoblastic T-cell lymphoma. He developed severe diarrhea and abdominal pain that persisted for more than 4 months. We suspected that he might have cord colitis syndrome (CCS), so metronidazole (MNZ) was administered. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12328-019-00959-xDOI Listing

[Interpretation of angioimmunoblastic T-cell lymphoma].

Authors:
Y M Guo M X He

Zhonghua Bing Li Xue Za Zhi 2019 Mar;48(3):261-264

Department of Pathology, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.03.022DOI Listing
March 2019
6 Reads

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Am J Hematol 2019 Mar 4. Epub 2019 Mar 4.

Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

The histological diagnosis of peripheral T-cell lymphoma (PTCL) can represent a challenge, particularly in the case of closely related entities such as angioimmunoblastic T-lymphoma (AITL), PTCL-not otherwise specified (PTCL-NOS), and ALK-negative anaplastic large-cell lymphoma (ALCL). Although gene expression profiling and next generations sequencing have been proven to define specific features recurrently associated with distinct entities, genomic-based stratifications have not yet led to definitive diagnostic criteria and/or entered into the routine clinical practice. Herein, to improve the current molecular classification between AITL and PTCL-NOS, we analyzed the transcriptional profiles from 503 PTCLs stratified according to their molecular configuration and integrated them with genomic data of recurrently mutated genes (RHOA , TET2, IDH2 , and DNMT3A) in 53 cases (39 AITLs and 14 PTCL-NOSs) included in the series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.25450DOI Listing
March 2019
3 Reads

ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma.

Cancer Cell Int 2019 14;19:32. Epub 2019 Feb 14.

1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing, 100142 People's Republic of China.

Background: Angioimmunoblastic T cell lymphoma (AITL) is a distinct subtype of peripheral T cell lymphoma and associated with poor outcomes. The activation status of T cell receptor (TCR) signaling has recently become a focus of attention in terms of the therapeutic targets. However, the molecular pathogenesis mechanisms and novel therapeutic targets are largely unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12935-019-0754-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6376795PMC
February 2019
3 Reads
1.989 Impact Factor

Effectiveness of cord blood transplantation for the treatment of refractory angioimmunoblastic T-cell lymphoma: a series of three cases.

Bone Marrow Transplant 2019 Feb 26. Epub 2019 Feb 26.

Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41409-019-0494-4DOI Listing
February 2019
2 Reads

American Registry of Pathology Expert Opinions: Immunohistochemical evaluation of classic Hodgkin lymphoma.

Ann Diagn Pathol 2019 Feb 6;39:105-110. Epub 2019 Feb 6.

Mayo Clinic, Rochester, MN, United States of America.

The diagnosis of classic Hodgkin lymphoma requires immunohistochemical confirmation in most cases and one can argue for these studies as standard-of-care in the diagnostic workup. The authors propose a panel of studies for primary identification of CHL to include: CD3, CD20, CD15, CD30 and PAX5. When pattern discordances are identified, additional assessment is recommended. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2019.02.001DOI Listing
February 2019
1 Read

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Blood 2019 Apr 19;133(15):1664-1676. Epub 2019 Feb 19.

Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE.

Peripheral T-cell lymphoma (PTCL) is a group of complex clinicopathological entities, often associated with an aggressive clinical course. Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the 2 most frequent categories, accounting for >50% of PTCLs. Gene expression profiling (GEP) defined molecular signatures for AITL and delineated biological and prognostic subgroups within PTCL-NOS (PTCL-GATA3 and PTCL-TBX21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-872549DOI Listing
April 2019
15 Reads
10.452 Impact Factor

New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.

Expert Rev Hematol 2019 Mar 27;12(3):137-146. Epub 2019 Feb 27.

a Center for Lymphoid Malignancies, Division of Hematology and Oncology, Department of Medicine , Columbia University Medical Center, College of Physicians and Surgeons , New York , NY , USA.

Introduction: The peripheral T-cell lymphomas (PTCL) are a rare and heterogeneous group of non-Hodgkin lymphomas originating from mature T- and NK-cells. They are aggressive diseases often resistant to chemotherapy. Areas Covered: The methodology of this review involves a literature search of data published on PubMed, abstracts from international conferences, and our own research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583102DOI Listing
March 2019
8 Reads

Successful treatment with mogamulizumab of refractory/relapsed angioimmunoblastic T-cell lymphoma following autologous stem cell transplantation.

Leuk Lymphoma 2019 Feb 8:1-3. Epub 2019 Feb 8.

a Division of Hematology , Japanese Red Cross Society Wakayama Medical Center , Wakayama , Wakayama , Japan.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1537489DOI Listing
February 2019
7 Reads

Immunoglobulinopathies in patients with angioimmunoblastic T-cell lymphoma.

Ter Arkh 2018 Aug;90(7):51-56

National Research Center for Hematology, Russian Federation, Moscow, Russia.

Aim: The aim of the study was to characterize quantitative and qualitative immunoglobulinopathies in patients with AITL at the onset of the disease.

Materials And Methods: 55 patients with newly diagnosed AITL were enrolled in the study, the male/female ratio was 30/25; median age was 61 (29-81) years. Diagnosis was based on standard WHO criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.26442/terarkh201890751-56DOI Listing
August 2018
8 Reads

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Cancer 2019 May 29;125(9):1507-1517. Epub 2019 Jan 29.

University of Washington Medical Center, Seattle, Washington.

Background: The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T-cell lymphomas (PTCLs) is not well defined. This study analyzed the impact of ASCT on the clinical outcomes of patients with newly diagnosed PTCL in CR1.

Methods: Patients with newly diagnosed, histologically confirmed, aggressive PTCL were prospectively enrolled into the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) study, and those in CR1 were included in this analysis. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.31861
Publisher Site
http://dx.doi.org/10.1002/cncr.31861DOI Listing
May 2019
10 Reads

Guillain Barré syndrome heralding the diagnosis of angioimmunoblastic T-cell lymphoma.

Leuk Lymphoma 2019 Jan 16:1-4. Epub 2019 Jan 16.

b Memorial Sloan Kettering Cancer Center , New York , NY , United States.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1553299DOI Listing
January 2019
8 Reads

[T follicular helper/B/follicular dendritic cell localization is useful in the diagnosis of angioimmunoblastic T cell lymphoma].

Zhonghua Bing Li Xue Za Zhi 2019 Jan;48(1):40-42

Department of Hematology, the Second People's Hospital of Lianyungang, Lianyungang 222006, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0529-5807.2019.01.009DOI Listing
January 2019
3 Reads

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.

J Hematol Oncol 2019 Jan 10;12(1). Epub 2019 Jan 10.

Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, 9200 W. Wisconsin Avenue, Suite C5500, 8701 W. Watertown Plank Rd, Milwaukee, WI, 53226, USA.

Background: There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT.

Methods: We evaluated 249 adult AITL patients who received their first allo-HCT during 2000-2016. Read More

View Article

Download full-text PDF

Source
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-
Publisher Site
http://dx.doi.org/10.1186/s13045-018-0696-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329157PMC
January 2019
24 Reads
4.812 Impact Factor

A case of AITL complicated by EBV-positive B cell and monoclonal plasma cell proliferation and effectively treated with lenalidomide.

Int J Hematol 2019 Apr 2;109(4):499-504. Epub 2019 Jan 2.

Department of Hematology, Tazuke Kofukai Medical Research Institute, Kitano Hospital, 2-4-20 Ohgimachi, Kita-ku, Osaka, 530-8480, Japan.

Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of peripheral T-cell lymphoma with an aggressive clinical course and poor prognosis after conventional chemotherapy, for which there is no current standard of care. We describe here an 87-year-old woman with AITL, whose clinical diagnosis was complicated by the presence of B immunoblasts positive for Epstein-Barr virus in the lymph nodes and monoclonal plasma cells in the bone marrow at initial presentation. Rebiopsy of the lymph node led to the correct diagnosis of AITL with concurrent smoldering plasma cell myeloma. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-02587-6
Publisher Site
http://dx.doi.org/10.1007/s12185-018-02587-6DOI Listing
April 2019
3 Reads

Angioimmunoblastic T-Cell Lymphoma.

Cancer Treat Res 2019;176:99-126

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York City, USA.

Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common types of T-cell lymphoma, representing about 15-20% of cases of peripheral T-cell lymphoma (PTCL). It is characterized by a unique clinical presentation and distinct pathologic and molecular features. Classes of drugs particularly active in AITL are emerging; however, treatment of relapsed and refractory disease remains a challenge. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99716-2_5
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99716-2_5DOI Listing
January 2019
14 Reads

Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.

Cancer Treat Res 2019;176:31-68

Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.

Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_2DOI Listing
January 2019
1 Read

Interleukin-17-producing angioimmunoblastic T-cell lymphoma with Evans syndrome.

Br J Haematol 2019 Jan 28;184(2):122. Epub 2018 Dec 28.

Division of Haematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjh.15733
Publisher Site
http://dx.doi.org/10.1111/bjh.15733DOI Listing
January 2019
7 Reads

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas.

Cancer Manag Res 2018 6;10:6731-6742. Epub 2018 Dec 6.

Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA,

Peripheral T-cell lymphomas (PTCLs) are an aggressive and diverse group of lymphomas with a T-cell origin. Most patients progress following initial treatment and require salvage therapy. The burden of symptoms is high due to its extra-nodal presentation, high rate of advanced disease, and associated cytopenias combined with its predilection for an elderly population. Read More

View Article

Download full-text PDF

Source
https://www.dovepress.com/hematologic-toxicity-is-rare-in-re
Publisher Site
http://dx.doi.org/10.2147/CMAR.S149241DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289206PMC
December 2018
10 Reads

Differentiation of angioimmunoblastic T-cell lymphoma from DRESS syndrome.

J Allergy Clin Immunol Pract 2018 Dec 14. Epub 2018 Dec 14.

Division of Allergy, Asthma, and Clinical Immunology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.11.048DOI Listing
December 2018
3 Reads

[Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].

Magy Onkol 2018 Dec 15;62(4):204-213. Epub 2018 Oct 15.

Gyermekgyógyászati Intézet, Gyermekhematológiai-onkológiai nem önálló Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Hungary.

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. Read More

View Article

Download full-text PDF

Source
December 2018
11 Reads

IMMUNE RECOVERY UVEITIS-LIKE SYNDROME MIMICKING RECURRENT T-CELL LYMPHOMA AFTER AUTOLOGOUS BONE MARROW TRANSPLANT.

Retin Cases Brief Rep 2018 Nov 26. Epub 2018 Nov 26.

Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio.

Purpose: To report the multimodal imaging findings of immune recovery uveitis mimicking recurrent T-cell lymphoma after autologous bone marrow transplant therapy.

Methods: A 71-year-old man presented with posterior uveitis 6 weeks after chemotherapy and autologous bone marrow transplant for angioimmunoblastic T-cell lymphoma. Multimodal imaging included fluorescein angiography, fundus autofluorescence, and optical coherence tomography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICB.0000000000000829DOI Listing
November 2018
5 Reads

Antidiuretic hormone- and interleukin-6-producing angioimmunoblastic T-cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion.

Br J Haematol 2019 Jan 28;184(2):121. Epub 2018 Nov 28.

Division of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama-shi, Osaka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15689DOI Listing
January 2019
3 Reads

Bexarotene in Patients With Peripheral T-cell Lymphomas: Results of a Retrospective Study.

Clin Lymphoma Myeloma Leuk 2019 Feb 13;19(2):109-115. Epub 2018 Oct 13.

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address:

Background: Peripheral T-cell lymphomas (PTCLs) are generally aggressive non-Hodgkin lymphomas that portend poor prognosis with currently available therapies. Bexarotene, a retinoic acid derivative, has efficacy in cutaneous T-cell lymphomas, but its activity in PTCL is unknown.

Patients And Methods: We conducted a retrospective, single-institution, review of off-label bexarotene therapy in patients with PTCL between 2005 and 2016. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S21522650183047
Publisher Site
http://dx.doi.org/10.1016/j.clml.2018.10.001DOI Listing
February 2019
15 Reads

Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma.

Int J Hematol 2019 Feb 14;109(2):175-186. Epub 2018 Nov 14.

Department of Oncology and Hematology, Shimane University Hospital, Izumo, Japan.

High-dose chemotherapy with autologous stem cell transplantation (HDC-ASCT) is an option for patients with peripheral T-cell lymphoma (PTCL); however, neither prospective nor retrospective studies support proceeding with ASCT upfront, and the timing of HDC-ASCT remains controversial. We retrospectively analyzed the risk factors for outcomes of 570 patients with PTCL, including PTCL not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL), who received ASCT for frontline consolidation (n = 98 and 75, respectively) or alternative therapies after either relapse (n = 112 and 75) or primary induction failure (PIF; n = 127 and 83) between 2000 and 2015. Significant risk factors for overall survival (OS) after upfront ASCT were a ≥ 2 prognostic index for T-cell lymphoma (P < 0. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12185-018-2560-x
Publisher Site
http://dx.doi.org/10.1007/s12185-018-2560-xDOI Listing
February 2019
8 Reads

Angioimmunoblastic T-cell lymphoma mimicking diffuse large B-cell lymphoma.

Cutis 2018 Sep;102(3):179-182

Department of Dermatology, Saint Joseph Mercy Hospital, Ann Arbor, Michigan, USA.

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive form of peripheral T-cell lymphoma that is characterized by lymphadenopathy, night sweats, fever, weight loss, and autoimmune phenomena. Cutaneous manifestations are present in up to 50% of cases, but few cases are reported in the dermatologic literature. We present a case of AITL that manifested in the skin. Read More

View Article

Download full-text PDF

Source
September 2018
8 Reads

Cutaneous localization of angioimmunoblastic T-cell lymphoma may masquerade as B-cell lymphoma or classical Hodgkin lymphoma: A histologic diagnostic pitfall.

J Cutan Pathol 2019 Feb 10;46(2):102-110. Epub 2018 Dec 10.

Département de Biopathologie, CHU Montpellier, Hôpital Gui De Chauliac, Montpellier, France.

Background: We report the cases of three patients presenting skin lesions whose biopsies showed nodular polymorphic infiltrates consisting of lymphocytes, plasma cells, histiocytes, eosinophils, B blasts, and Hodgkin Reed-Sternberg (HRS)-like cells. Two of them were initially diagnosed as classical Hodgkin lymphoma (cHL), on the other hand, the last one as a B-cell lymphoma. All patients have been treated for angioimmunoblastic T-cell lymphoma (AITL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13382DOI Listing
February 2019
8 Reads

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Cancer 2019 Jan 17;125(1):99-108. Epub 2018 Oct 17.

Early Phase Trials Unit, Churchill Hospital, University of Oxford, Oxford, United Kingdom.

Background: In the current study, the authors sought to determine the maximum tolerated dose (MTD) of the novel class 1 selective histone deacetylase inhibitor CXD101 in a dose escalation study in patients with advanced solid tumors or recurrent/refractory lymphoma.

Methods: The authors escalated the dose of CXD101 from 1 mg twice daily orally for 5 days in a 21-day cycle (3+3 design).

Results: A total of 39 patients were enrolled, 36 of whom received CXD101. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.31791DOI Listing
January 2019
12 Reads

Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma.

Cytokine 2019 Jan 14;113:371-379. Epub 2018 Oct 14.

Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University, Seoul, Republic of Korea; Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

To better predict the outcomes of patients with peripheral T-cell lymphoma (PTCL), we measured the levels of various cytokines in serum samples from patients with PTCL and analyzed their clinical outcomes. We measured 34 cytokines in samples from 121 PTCL patients (55 PTCL-not otherwise specified (NOS), 44 angioimmunoblastic T-cell lymphoma (AITL), and 22 ALK anaplastic large cell lymphoma) at diagnosis. Their impact on clinical outcomes, including overall survival and complete response rate, were analyzed with other clinical variables. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cyto.2018.10.009DOI Listing
January 2019

Noncaseating suppurative granulomatous lymphadenitis in adult onset Still's disease - a diagnostic dilemma in a tuberculosis-endemic region: a case report.

J Med Case Rep 2018 Oct 15;12(1):299. Epub 2018 Oct 15.

Sri Jayewardenepura General Hospital and Post-graduate Training Institute, Sri Jayawardenepura Kotte, Western Province, Sri Lanka.

Background: Lymphadenopathy is not an uncommon presentation of adult onset Still's disease: it is present in up to two thirds of patients with adult onset Still's disease. The characteristic appearance of lymphadenopathy is described as intense, paracortical immunoblastic hyperplasia. Changes in light microscopy may resemble lymphoma, but immunohistochemistry reveals a benign polyclonal B cell hyperplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13256-018-1816-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192002PMC
October 2018
4 Reads

Intestinal T-cell and NK/T-cell lymphomas: A clinicopathological study of 27 Chinese patients.

Ann Diagn Pathol 2018 Dec 9;37:107-117. Epub 2018 Oct 9.

Department of Pathology, Xinqiao Hospital, Third Military Medical University, Chongqing, China. Electronic address:

Background: Intestinal T-cell and NK/T- cell lymphomas are rare and aggressive. The diagnosis is quite difficult, especial in biopsy specimens. This study investigates the clinicopathological features of intestinal T-cell and NK/T-cell lymphomas to aid their differential diagnosis. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10929134183013
Publisher Site
http://dx.doi.org/10.1016/j.anndiagpath.2018.10.004DOI Listing
December 2018
13 Reads
1.110 Impact Factor

Cutaneous angioimmunoblastic T-cell lymphoma: Epstein-Barr Virus positivity and its effects on clinicopathological features.

J Am Acad Dermatol 2018 Sep 18. Epub 2018 Sep 18.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Electronic address:

Background: Epstein-Barr virus (EBV) positivity frequently presents in patients with nodal angioimmunoblastic T-cell lymphoma (AITL). However, the presence of EBV in skin lesions and its clinicopathological significance have not been evaluated.

Objective: To analyze the clinical and histopathological features of cutaneous AITL and evaluate EBV-positivity in skin tissue and its effects on clinicopathological features of AITL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.08.053DOI Listing
September 2018
5 Reads

Hemophagocytic lymphohistiocytosis presenting with annular erythema multiforme-like eruptions in a patient with angioimmunoblastic T cell lymphoma: A case report.

Exp Ther Med 2018 Sep 6;16(3):2060-2065. Epub 2018 Jul 6.

Department of Hematology and Oncology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, P.R. China.

Angioimmunoblastic T cell lymphoma (AITL)-associated hemophagocytic lymphohistiocytosis (HLH) rarely occurs with annular erythema multiforme-like rashes. The present case report describes a patient who was misdiagnosed with erythema multiforme at an early stage of the disease due to annular erythema multiforme-like eruptions. However, antihistamine treatment was ineffective. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6420DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122190PMC
September 2018
6 Reads

Peripheral T-Cell Lymphomas: Incorporating New Developments in Diagnostics, Prognostication, and Treatment Into Clinical Practice-PART 2: ENKTL, EATL, Indolent T-Cell LDP of the GI Tract, ATLL, and Hepatosplenic T-Cell Lymphoma.

Oncology (Williston Park) 2018 08 15;32(8):e83-e89. Epub 2018 Aug 15.

The World Health Organization classification for peripheral T-cell lymphomas (PTCLs) continues to evolve based on genetic and clinical distinctions of each entity. In Part 1, an overview was provided of PTCL not otherwise specified, follicular T-cell lymphoma, angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), and breast implant-associated ALCL. In Part 2, this review is extended to extranodal natural killer (NK)/T-cell lymphoma, enteropathy-associated T-cell lymphoma, indolent T-cell lymphoproliferative disorder of the gastrointestinal tract, adult T-cell leukemia/lymphoma, and hepatosplenic T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
August 2018
4 Reads

B2 microglobulin is a novel prognostic marker of Angioimmunoblastic T-cell lymphoma.

Sci Rep 2018 Aug 27;8(1):12907. Epub 2018 Aug 27.

Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

The aim of the present study was to analyze features and explore parameters that can help to predict prognosis for angioimmunoblastic T-cell lymphoma (AITL). A total of 117 patients with AITL were retrospectively analyzed. Multivariate analysis showed that β2 microglobulin (β2-M) ≥4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-31212-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110724PMC

Angioimmunoblastic T-cell lymphoma presenting with extensive marrow plasmacytosis and hypergammaglobulinaemia: a diagnostic challenge.

Pathology 2018 10 22;50(6):665-668. Epub 2018 Aug 22.

Department of Medical Oncology and Hematology, Medanta - The Medicity Hospital, Gurgaon, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2018.03.014DOI Listing
October 2018
2.190 Impact Factor

Candidate susceptibility variants in angioimmunoblastic T-cell lymphoma.

Fam Cancer 2019 01;18(1):113-119

Department of Medical and Clinical Genetics, Medicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver mutations have been found in TET2, IDH2, DNMT3A, RHOA, FYN, PLCG1, and CD28, whereas germline susceptibility to AITL has to our knowledge not been studied. The homogenous Finnish population is well suited for studies on genetic predisposition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10689-018-0099-xDOI Listing
January 2019
1 Read

Chylous ascites, anti-interferon-gamma autoantibody, and angioimmunoblastic T-cell lymphoma: a rare but intriguing connection over Mycobacterium avium.

Med Microbiol Immunol 2019 Feb 6;208(1):33-37. Epub 2018 Aug 6.

Department of Hematology, Shiga University of Medical Science, Otsu, Shiga, Japan.

We report a case of non-AIDS (acquired immunodeficiency syndrome), non-CAPD (Continuous Ambulatory Peritoneal Dialysis), non-cirrhotic, Mycobacterium avium peritonitis, which is a rare form of mycobacterial infection. A 66-year-old Japanese man who had been treated previously for angioimmunoblastic T-cell lymphoma (AITL), had developed disseminated M. avium infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00430-018-0555-0DOI Listing
February 2019
4 Reads